Navitoclax (ABT‐263), targeting BCL‐2/BCL‐XL, has shown efficacy in combination with standard therapies in lymphoma and small cell lung cancer but has thrombocytopenia as a dose‐limiting toxicity due to BCL‐XL inhibition.201, 202. Here, BCL2L1 is linked to lymphoma.